PCP extracts ameliorated NAFLD by reshaping the gut microbiota through the reduction of BSH-producing bacteria, which decreased BA deconjugation and increased fecal taurine-conjugated BAs, and by inhibiting ileal FXR/FGF15 while activating hepatic FXR/BSEP/CYP27A1 (Li et al., 2022a). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.